SciELO - Scientific Electronic Library Online

vol.44 número1Prestación farmacéutica especializada en centros sociosanitarios en EspañaAdministración intrapleural secuencial de agentes fibrinolíticos y dornasa alfa en el empiema. Protocolo de uso clínico en base a su estabilidad fisicoquímica índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados




Links relacionados

  • En proceso de indezaciónCitado por Google
  • No hay articulos similaresSimilares en SciELO
  • En proceso de indezaciónSimilares en Google


Farmacia Hospitalaria

versión On-line ISSN 2171-8695versión impresa ISSN 1130-6343


EDO-SOLSONA, María Dolores; VITORIA-MINANA, Isidro  y  POVEDA-ANDRES, José-Luis. Implementation and results of a risk-sharing scheme for enzyme replacement therapy in lysosomal storage diseases. Farm Hosp. [online]. 2020, vol.44, n.1, pp.10-15.  Epub 06-Jul-2020. ISSN 2171-8695.


To describe a risk-sharing program's implementation and results on enzyme replacement therapy for lysosomal diseases.


The program was designed and implemented in a referral hospital for congenital metabolic diseases. The conclusion of agreements required the following phases: 1) To define and agree on response variables and criteria to treatment; 2) to assign discount percentage to each stage of effectiveness; 3) to prepare and sign the agreement by all parties; 4) to implement the agreement; 5) to individualize purchases management; 6) to evaluate clinical results, and 7) to issue an annual report.


Eight patients were included in the program (four with Hurler's disease, two with Pompe and two with Gaucher), five of them were women and three were men. After analyzing the defined variables and response criteria, all patients presented full effectiveness after two or three years of follow-up except one of them that could not be evaluated. Given the effectiveness achieved, the hospital made full payment of all administered therapies.


The implanted risk-sharing program is Spain's first published event of paying for clinical results using orphan drugs. Economic impact has been limited, and program implementation has gone through a complex process of formulation and management. However, the greatest achievement has been to reduce the knowledge gap between efficacy and effectiveness, stating that the therapies administered have shown the optimal benefits for which the funder is willing to pay.

Palabras clave : Risk-sharing agreements; Orphan drugs; Enzyme replacement therapies; Health outcomes; Effectiveness; Access.

        · resumen en Español     · texto en Español | Inglés     · Español ( pdf ) | Inglés ( pdf )